Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

NCT06650332 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Metastatic HER2 Positive Gastroesophageal Junction Cancer

Interventions

DRUG: cadonilimab
DRUG: Trastuzumab
DRUG: XELOX
DRUG: Disitamab Vedotin
DRUG: mFOLFOX6

Sponsor

Zhejiang Cancer Hospital